MS arising during Tocilizumab therapy for rheumatoid arthritis

Conclusion: This case illustrates that Tocilizumab might cause secondary auto-immunity in CNS. It is important to be aware of this potential complication as anti-IL6 therapy might become an option for the treatment NMOSD.
Source: Multiple Sclerosis - Category: Neurology Authors: Tags: Case Report and Clinical Commentary Source Type: research